AstraZeneca boosts open innovation efforts


Astrazeneca (AZ) has launched a new web portal, bringing together new and existing open innovation programmes. The aim is to make collaboration with academics, other companies, governments and non-government organisations easier.

Like a growing number of pharmaceutical companies, AZ already collaborates extensively with academics and other organisation. However, it wants to open up these programmes and encourage potential collaborators. AZ will offer access to its compound library, tool compounds for biological investigations, screening for target validation and various other services. There will also be rewards for researchers who suggest solutions for challenges the company is facing.

‘To push the boundaries of science and deliver new medicines to patients, we need to create a more permeable research environment,’ said AZ’s Mene Pangalos in a statement. ‘An essential part of that is making our knowledge and compounds more accessible.’

This move follows several similar initiatives from other companies: most notably GlaxoSmithKline, which has opened up extensive chunks of its compound libraries and runs collaborative drug discovery contests; Eli Lilly, which has ongoing target-based and phenotypic screening services available to potential collaborators; and a consortium of Japanese firms.


Related Content

The hunt for innovation

31 January 2014 Premium contentFeature

news image

Big pharma companies are embracing a more open and collaborative approach. Nuala Moran discovers who’s working with whom

Data-sharing partnership for drug discovery

28 June 2013 Business

news image

Collaborative project aims to assist medicinal chemistry efforts

Most Read

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

The mothers of invention

24 February 2015 Managing Change

news image

Nina Notman profiles four researchers successfully balancing an academic career with family life

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Hepatitis C drug patent challenged in Europe

19 February 2015 Business

news image

Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent